Anti-Actin IgA has recently garnered attention in the medical community as a potential biomarker for certain autoimmune and gastrointestinal disorders.
In this article, we will delve into the significance of Anti-Actin IgA, exploring its role in diagnosis and disease management with a focus on understanding what Anti-Actin IgA is, its clinical relevance, and how it can be utilized in healthcare.
This is an IgA type of antibody against actin, a protein that is a fundamental component of cellular structure and function. The presence and levels of Anti-Actin IgA in the blood can provide valuable insights into autoimmune processes, especially those affecting the gastrointestinal system.
Anti-Actin IgA refers to an IgA type of autoantibody that targets actin, a vital protein found in all human cells. They are the main type of smooth muscle antibodies. [2.]
Actin is an essential structural protein in eukaryotic cells. As a major component of cellular microfilaments, it is vital in proper cell structure, movement and division. Cellular microfilaments are an essential part of the cell’s cytoskeleton, providing structural support to cells and enabling cell movement.
In the setting of increased inflammation which is commonly seen in many autoimmune conditions, cell damage occurs which exposes the cellular cytoskeleton to increasing numbers of anti-actin IgA antibodies. Cellularly this manifests as distortion of the actin network and the appearance of parallel “stress fibers” on imaging of affected cells. Villous atrophy, or loss of intestinal mucosa, is seen in the intestinal luminal surface. [7.]
In autoimmune disorders, the binding of anti-actin antibodies to structural cellular components causes cell damage that can further contribute to the pathophysiology of the disease, increasing inflammation, tissue damage, and impaired organ function. This damage stimulates the production of more anti-actin IgA antibodies, driving the pathology forward.
The presence of Anti-Actin IgA can indicate an autoimmune response; anti-actin antibodies are commonly seen in celiac disease and autoimmune hepatitis. [7., 12.]
The clinical significance of Anti-Actin IgA lies primarily in its association with the pathology behind gastrointestinal autoimmune disorders such as Celiac disease and autoimmune hepatitis.
The level of these antibodies can correlate with the severity of the disease, making them a useful marker for clinicians in managing patient treatment plans.
The presence of anti-actin IgA antibodies in celiac disease can inform the degree of villous atrophy present. [4.] The presence of anti-actin IgA can help in the diagnosis and monitoring of disease activity, and may help guide treatment decisions.
There are two main types of autoimmune hepatitis. Type 1 AIH is much more prevalent, comprising 90% of cases, and is associated with the presence of Anti-smooth muscle antibodies such as anti-actin antibodies as well as the co-presence of autoimmune thyroid disease, celiac disease, and/or ulcerative colitis. [5.]
In contrast, type 2 AIH comprises only 5% or less of adult cases of AIH, but up to 38% of pediatric cases. It is associated with the presence of a different set of autoantibodies against liver and/or kidney cells, as well as the co-presence of autoimmune thyroid disease, type 1 diabetes and/or autoimmune skin conditions. [5.]
Overwhelmingly, women are more affected by AIH (80% of cases). AIH tends to respond well to immunosuppression. [9.]
The production of Anti-Actin IgA in the body is a result of a complex immune response.
Generally speaking, autoantibody production and loss of self-tolerance involve a complex interplay between central and peripheral tolerance mechanisms that occur during immune cell development.
Among mature immune cells, breakdown of tolerance to self-antigens or altered self-antigens may come from failure to clear apoptotic debris, inflammation-induced modifications of self-antigens, or cross-reactivity with foreign antigens.
Certain autoantibodies exhibit cross-reactivity between intracellular antigens and surface or extracellular antigens, perpetuating B cell activation and autoantibody-driven damage.
Following autoantibody initiation, inflammation may induce the release of intracellular or modified self-antigens, prompting antibody-mediated injury and the expansion of autoreactive B cell populations.
Ultimately, these processes involve various autoantibody isotypes and lead to chronic inflammation and tissue damage, perpetuating autoimmune disease pathology.
Various factors can influence the production of anti-actin IgA.
Genetic predispositions may play a role, as certain individuals are more likely to develop autoimmune responses due to their genetic makeup.
Environmental factors including diet, and possibly certain infections, can also contribute to triggering the immune system to produce these autoantibodies. This is well-illustrated in the case of celiac disease, where chronic exposure to the gluten protein and its breakdown products stimulates the inflammation cascade and prompts autoantibody production.
Additionally, chronic inflammation as often seen in autoimmune conditions generally, might enhance the production of Anti-Actin IgA. This may be part of what drives the progression of type 1 autoimmune hepatitis, which often co-occurs with other autoimmune conditions including celiac disease, autoimmune thyroid disease and ulcerative colitis.
Laboratory testing for Anti-Actin IgA is primarily indicated in the evaluation and management of certain autoimmune and gastrointestinal disorders like celiac disease and autoimmune hepatitis.
The measurement of Anti-Actin IgA is typically conducted through blood serum testing. The methodologies used in these tests can vary, with some employing advanced techniques like enzyme-linked immunosorbent assay (ELISA) to ensure specificity and sensitivity.
This test typically requires a venipuncture.
It is important to consult with the ordering company regarding their reference ranges used. One company reports results for Anti-actin IgA antibodies as: [1.]
Negative: <20
Borderline: 21.0-24.9
Positive ≥ 25 Units
Exploring related biomarkers alongside Anti-Actin IgA provides a broader perspective on diagnosing and understanding autoimmune and gastrointestinal disorders.
Diagnostic testing for celiac disease can include: [6.]
Serologic Testing: in addition to anti-actin IgA which can assess the damage to intestinal villi, other antibodies to test for include anti-TTG (anti-tissue transglutaminase) IgG and IgA; anti-DGP (deamidated gliadin peptide) IgG; and total IgA levels.
Genetic Testing: genetic testing may be performed for human leukocyte antigens (HLA-DQ2 and HLA-DQ8) [11.]
Imaging and Biopsy: additionally, an endoscopy and/or colonoscopy with biopsy may be performed.
Diagnostic testing for autoimmune hepatitis requires confirming an autoimmune hepatitis process, ruling out other causes of hepatitis, and assessing for comorbid conditions.
Biopsy: a biopsy of affected tissue demonstrating histologic findings consistent with lymphoplasmacytic interface hepatitis is required
Serologic Testing: elevated liver enzymes and other autoantibody tests, along with test results that rule out the possibility of other causes including infections, cholestatic disease, metabolic, hereditary or drug-induced disease are required
Addressing elevated anti-actin IgA levels involves a combination of medical intervention and lifestyle modifications with a focus on reducing the inflammation that drives autoimmune conditions.
Medical treatments for conditions associated with elevated anti-actin IgA levels is essential. This can include the use of immunosuppressants or anti-inflammatory medications, particularly in the management of inflammatory bowel diseases.
In celiac disease, a strict gluten-free diet is a primary treatment approach.
These medical interventions aim to reduce inflammation, alleviate symptoms, and normalize Anti-Actin IgA levels.
The following diet and lifestyle modifications can support healthy immune function and reduce inflammatory levels.
Anti-inflammatory Diet: [14.]
Gut Health Support: [3.]
Manage Stress: [10.]
Avoid Trigger Foods: [8.]
Click here to compare tests and order testing to assess for the presence of autoimmune antibodies.
[1.] Actin IgA (F-Actin) ELISA. Trinity Biotech plc is a public company, specialising in the development, manufacture and marketing of clinical diagnostic products. Accessed March 27, 2024. https://www.trinitybiotech.com/reference-lab-tests/actin-iga-f-actin-elisa/
[2.] Ayadi I, Laadhar L, Kallel-Sellami M. SAT0108 Clinical significance of anti-actin antibodies in autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases. 2017;76(Suppl 2):809-810. doi:https://doi.org/10.1136/annrheumdis-2017-eular.6748
[3.] Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The Gut Microbiota and Inflammation: An Overview. Int J Environ Res Public Health. 2020 Oct 19;17(20):7618. doi: 10.3390/ijerph17207618. PMID: 33086688; PMCID: PMC7589951.
[4.] Carroccio A, Brusca I, Iacono G, et al. IgA anti-actin antibodies ELISA in coeliac disease: A multicentre study. Digestive and Liver Disease. 2007;39(9):818-823. doi:https://doi.org/10.1016/j.dld.2007.06.004
[5.] DynaMedex. www.dynamedex.com. Accessed March 27, 2024. https://www.dynamedex.com/condition/autoimmune-hepatitis
[6.] DynaMedex. www.dynamedex.com. Accessed March 27, 2024. https://www.dynamedex.com/condition/celiac-disease#GUID-67DEEB3A-0675-4F88-AB11-E407C7B9DD40
[7.] Granito A, Muratori P, Cassani F, Pappas G, Muratori L, Agostinelli D, Veronesi L, Bortolotti R, Petrolini N, Bianchi FB, Volta U. Anti-actin IgA antibodies in severe coeliac disease. Clin Exp Immunol. 2004 Aug;137(2):386-92. doi: 10.1111/j.1365-2249.2004.02541.x. PMID: 15270857; PMCID: PMC1809109.
[8.] Ohtsuka Y. Food intolerance and mucosal inflammation. Pediatr Int. 2015;57(1):22-9. doi: 10.1111/ped.12546. PMID: 25442377.
[9.] Schotte H, Willeke P, Schmalhorst J, Schlüter B. Diagnostic Performance of an Anti-Actin Autoantibody Binding Enzyme Immunodot Blot in Autoimmune Hepatitis Type 1. J Clin Lab Anal. 2016 Mar;30(2):123-9. doi: 10.1002/jcla.21825. Epub 2014 Nov 25. PMID: 25425293; PMCID: PMC6806702.
[10.] Sidik S. Chronic stress can inflame the gut — now scientists know why. Nature. Published online May 25, 2023. doi:https://doi.org/10.1038/d41586-023-01700-y
[11.] Siddiqui K, Uqaili AA, Rafiq M, Bhutto MA. Human leukocyte antigen (HLA)-DQ2 and -DQ8 haplotypes in celiac, celiac with type 1 diabetic, and celiac suspected pediatric cases. Medicine (Baltimore). 2021 Mar 19;100(11):e24954. doi: 10.1097/MD.0000000000024954. PMID: 33725967; PMCID: PMC7982179.
[12.] Silvestrini RA, Benson EM: Whither smooth muscle antibodies in the third millennium. J Clin Pathol 2001; 54(9):677-678.
[13.] Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015 Jun;125(6):2194-202. doi: 10.1172/JCI78084. Epub 2015 May 4. PMID: 25938780; PMCID: PMC4497746.
[14.] Tsigalou C, Konstantinidis T, Paraschaki A, Stavropoulou E, Voidarou C, Bezirtzoglou E. Mediterranean Diet as a Tool to Combat Inflammation and Chronic Diseases. An Overview. Biomedicines. 2020 Jul 8;8(7):201. doi: 10.3390/biomedicines8070201. PMID: 32650619; PMCID: PMC7400632.